Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
TK5Buws8YsTa3Bue